Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug
Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug
神經分泌生物科學表示，美國FDA已接受對腎上腺腺體疾病藥物的優先審查新藥申請
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊